计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
Entinostat (MS-275)对HDAC1和HDAC3抑制作用强于与HDACs 4, 6, 8,和10,IC50分别为0.51 μM和1.7 μM。An HDAC inhibitor shown to inhibit angiogenesis and metastasis.
Information
Entinostat (MS-275, SNDX-275) strongly inhibitsHDAC1andHDAC3withIC50of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Entinostat inducesautophagyandapoptosis. Phase 3.
In vitro
MS-275 shows inhibitory to HDACs by 2\'-amino group. MS-275 induces accumulation of p21WAF1/CIP1 and gelsolin in K562 cell. MS-275 could reduce S-phase cells and induce G1-phase cells in A2780 cell. MS-275 inhibits the proliferation of human tumor cell lines including A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 with IC50 from 41.5 nM to 4.71 μM, which due to HAD-inhibition. MS-275 is not sensitive to other HDACs (4, 6, 8 and 10) with IC50 about/above 100 μM. MS-275 shows great inhibition to human leukemia and lymphoma cells, including U937, HL-60, K562, and Jurkat. MS-275 also decreases expression of cyclin D1 and the antiapoptotic proteins Mcl-1 and XIAP.
In vivo
MS-275 exhibits great antitumor activity against human tumor xenografts except HCT-15 at 49 mg/kg. MS-275 demonstrates promising therapeutic potential in both solid and hematologic malignancies, as well as regulation of physiologic and aberrant gene expression. MS-275, combination with IL-2, has great antitumor activity to renal cell carcinoma xenograft model, which due to decreased T regulatory cells and increased splenocytes.
Cell Data
cell lines:
Concentrations:~ 10 μM
Incubation Time:3 days
Powder Purity:≥97%
| ALogP | 2 |
|---|
H227: 可燃液体
P210: 远离热源,热表面,火花,明火和其他点火源。 - 禁止抽烟。
P280: 戴防护手套/穿防护服/戴防护眼罩/戴防护面具。
P370+P378: 火灾时:使用干砂、干粉或抗醇泡沫灭火。
P403+P235: 存放在通风良好的地方。保持低温。
P501: 将内容物/容器送到批准的废物处理厂处理